Advertisement
Advertisement
U.S. markets close in 4 hours 32 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Intellia Therapeutics, Inc. (NTLA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
68.25+2.65 (+4.04%)
As of 11:28AM EDT. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close65.60
Open66.06
Bid67.66 x 800
Ask67.90 x 2200
Day's Range64.61 - 68.82
52 Week Range37.08 - 180.59
Volume298,668
Avg. Volume1,313,845
Market Cap5.188B
Beta (5Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)-5.06
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est124.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for NTLA

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Intellia Therapeutics, Inc.
    Analyst Report: Intellia Therapeutics, Inc.Intellia Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It’s evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.
    Rating
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
Advertisement
Advertisement